BR112014019349A8 - Previsão do resultado nos pacientes com doença pulmonar obstrutiva crônica - Google Patents
Previsão do resultado nos pacientes com doença pulmonar obstrutiva crônicaInfo
- Publication number
- BR112014019349A8 BR112014019349A8 BR112014019349A BR112014019349A BR112014019349A8 BR 112014019349 A8 BR112014019349 A8 BR 112014019349A8 BR 112014019349 A BR112014019349 A BR 112014019349A BR 112014019349 A BR112014019349 A BR 112014019349A BR 112014019349 A8 BR112014019349 A8 BR 112014019349A8
- Authority
- BR
- Brazil
- Prior art keywords
- patients
- parameter
- copd
- prognosis
- management
- Prior art date
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 238000012544 monitoring process Methods 0.000 abstract 3
- 238000004393 prognosis Methods 0.000 abstract 3
- 238000012502 risk assessment Methods 0.000 abstract 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 3
- 108010048233 Procalcitonin Proteins 0.000 abstract 2
- 239000000090 biomarker Substances 0.000 abstract 2
- 108010012004 proadrenomedullin Proteins 0.000 abstract 2
- 102000034567 proadrenomedullin Human genes 0.000 abstract 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 abstract 2
- 208000000059 Dyspnea Diseases 0.000 abstract 1
- 206010013975 Dyspnoeas Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
MÉTODO PARA O PROGNÓSTICO E/OU A AVALIAÇÃO DO RISCO E/OU O MONITORAMENTO DA TERAPIA E/OU O CONTROLE DE PACIENTES COM COPD, E USO DE AGENTES PARA PREPARAÇÃO DE UM KIT. A presente invenção refere-se a um método para o prognóstico e/ou a avaliação do risco e/ou o monitoramento da terapia e/ou o controle de pacientes com COPD o método compreendendo as etapas de: i) fornecer uma amostra de um fluido corporal do referido paciente, ii) determinar na referida amostra o nível de pelo menos um biomarcador, selecionado a partir do grupo consistindo em proadrenomedulina (proADM), peptídeo pro-natriurético, proVasopressina (proAVP) e Procalcitonina (PCT) ou seus fragmentos de pelo menos 12 aminoácidos de comprimento, iii) determinar um, dois ou três dos parâmetros do índice de BODE de índice de massa corporal (BMI, parâmetro de B), grau de obstrução do fluxo aéreo (FEV1, parâmetro de O), dispnéia (parâmetro de D) e capacidade de exercício (parâmetro de E), iv) correlacionar o referido nível do referido pelo menos um biomarcador determinado na etapa ii), em combinação com o referido um, dois ou três parâmetros do índice de BODE determinados na etapa iii) para o prognóstico e/ou a avaliação do risco e/ou o monitoramento da terapia e/ou o controle de pacientes com COPD.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12001590.4A EP2637023A1 (en) | 2012-03-08 | 2012-03-08 | Prediction of outcome in patients with chronic obstructive pulmonary disease |
PCT/EP2013/000558 WO2013131621A1 (en) | 2012-03-08 | 2013-02-26 | Prediction of outcome in patients with chronic obstructive pulmonary disease |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014019349A2 BR112014019349A2 (pt) | 2017-06-20 |
BR112014019349A8 true BR112014019349A8 (pt) | 2017-07-11 |
Family
ID=47780019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014019349A BR112014019349A8 (pt) | 2012-03-08 | 2013-02-26 | Previsão do resultado nos pacientes com doença pulmonar obstrutiva crônica |
Country Status (12)
Country | Link |
---|---|
US (1) | US20150080246A1 (pt) |
EP (3) | EP2637023A1 (pt) |
JP (1) | JP6117251B2 (pt) |
CN (1) | CN104126125B (pt) |
BR (1) | BR112014019349A8 (pt) |
DK (1) | DK2823314T3 (pt) |
ES (1) | ES2631653T3 (pt) |
HK (1) | HK1198556A1 (pt) |
IN (1) | IN2014DN07813A (pt) |
RU (1) | RU2688168C2 (pt) |
WO (1) | WO2013131621A1 (pt) |
ZA (1) | ZA201405610B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2637023A1 (en) | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
WO2016024278A1 (en) | 2014-08-14 | 2016-02-18 | Memed Diagnostics Ltd. | Computational analysis of biological data using manifold and a hyperplane |
CN106999097B (zh) * | 2014-11-12 | 2021-05-11 | 皇家飞利浦有限公司 | 用于评估受试者中的慢性阻塞性肺疾病copd严重度的装置和方法 |
CA2986097A1 (en) | 2015-05-18 | 2016-11-24 | The University Of British Columbia | Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd |
US11466331B2 (en) | 2016-03-03 | 2022-10-11 | Memed Diagnostics Ltd. | RNA determinants for distinguishing between bacterial and viral infections |
CN107229813A (zh) * | 2016-03-24 | 2017-10-03 | 深圳中迈数字医疗技术有限公司 | 实施监护的判断方法及系统 |
CN109661578B (zh) | 2016-07-10 | 2022-05-10 | 米密德诊断学有限公司 | 用于区分细菌和病毒感染的蛋白质特征 |
EP4184167A1 (en) | 2016-07-10 | 2023-05-24 | MeMed Diagnostics Ltd. | Early diagnosis of infections |
US11353456B2 (en) * | 2016-09-29 | 2022-06-07 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification for appendicitis |
CN110431425B (zh) * | 2017-02-02 | 2023-06-27 | B.R.A.H.M.S 有限公司 | proADM作为指示不良事件的标志物 |
WO2018191560A1 (en) * | 2017-04-12 | 2018-10-18 | Proterixbio, Inc. | Biomarker combinations for monitoring chronic obstructive pulmonary disease and/or associated mechanisms |
CN107267658B (zh) * | 2017-08-21 | 2018-11-02 | 常州市第二人民医院 | Copd诊断用分子标志物 |
EP3682246A1 (en) * | 2017-09-13 | 2020-07-22 | B.R.A.H.M.S GmbH | Method for guidance of fluid therapy based on proadrenomedullin |
EP3682236A1 (en) * | 2017-09-13 | 2020-07-22 | B.R.A.H.M.S GmbH | Proadrenomedullin as indicator for renal replacement therapy in critically ill patients |
BR112020004150A2 (pt) * | 2017-09-13 | 2020-09-08 | B.R.A.H.M.S Gmbh | pct e pro-adm como marcadores para monitorar tratamento de antibiótico |
EP3502706A1 (en) * | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin |
CN108424969B (zh) * | 2018-06-06 | 2022-07-15 | 深圳市颐康生物科技有限公司 | 一种生物标志物、诊断或预估死亡风险的方法 |
CN109218131B (zh) * | 2018-09-03 | 2022-03-29 | 平安医疗健康管理股份有限公司 | 网络监控方法、装置、计算机设备和存储介质 |
EP3914913A1 (en) * | 2019-02-21 | 2021-12-01 | B.R.A.H.M.S GmbH | Method for the diagnosis of macce in patients who underwent gastrointestinal surgery |
CN110850006B (zh) * | 2019-12-20 | 2020-11-20 | 河南中医药大学 | 一种慢性阻塞性肺病诊断试剂及试剂盒 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
SI2019965T1 (sl) * | 2006-05-02 | 2015-10-30 | Critical Care Diagnostics, Inc. | Diferencialna diagnoza med pljučno boleznijo in boleznijo srca in ožilja |
DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
DE102006053442A1 (de) * | 2006-11-12 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II |
DE102006060112A1 (de) * | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
US8815519B2 (en) * | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
PT2269063E (pt) * | 2008-04-18 | 2013-11-27 | Critical Care Diagnostics Inc | Predição do risco de eventos cardíacos adversos maiores |
WO2010054810A1 (en) * | 2008-11-11 | 2010-05-20 | B.R.A.H.M.S Ag | Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp |
GB0911007D0 (en) * | 2009-06-25 | 2009-08-12 | Univ Hospital Of North Staffordshire | Analyzer apparatus and methods for lung disease |
CN102253220B (zh) * | 2011-06-07 | 2014-04-09 | 复旦大学附属中山医院 | 用于诊断慢性阻塞性肺病急性加重期的试剂盒 |
EP2637023A1 (en) | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
-
2012
- 2012-03-08 EP EP12001590.4A patent/EP2637023A1/en not_active Withdrawn
-
2013
- 2013-02-26 RU RU2014140608A patent/RU2688168C2/ru active
- 2013-02-26 EP EP17000604.3A patent/EP3232201A1/en active Pending
- 2013-02-26 CN CN201380009139.6A patent/CN104126125B/zh active Active
- 2013-02-26 US US14/383,744 patent/US20150080246A1/en not_active Abandoned
- 2013-02-26 WO PCT/EP2013/000558 patent/WO2013131621A1/en active Application Filing
- 2013-02-26 JP JP2014560266A patent/JP6117251B2/ja active Active
- 2013-02-26 BR BR112014019349A patent/BR112014019349A8/pt not_active Application Discontinuation
- 2013-02-26 DK DK13707113.0T patent/DK2823314T3/en active
- 2013-02-26 IN IN7813DEN2014 patent/IN2014DN07813A/en unknown
- 2013-02-26 EP EP13707113.0A patent/EP2823314B1/en not_active Revoked
- 2013-02-26 ES ES13707113.0T patent/ES2631653T3/es active Active
-
2014
- 2014-07-29 ZA ZA2014/05610A patent/ZA201405610B/en unknown
- 2014-11-28 HK HK14112042.7A patent/HK1198556A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013131621A1 (en) | 2013-09-12 |
CN104126125B (zh) | 2017-03-01 |
ES2631653T3 (es) | 2017-09-01 |
WO2013131621A8 (en) | 2014-06-12 |
RU2688168C2 (ru) | 2019-05-20 |
BR112014019349A2 (pt) | 2017-06-20 |
CN104126125A (zh) | 2014-10-29 |
JP2015509596A (ja) | 2015-03-30 |
ZA201405610B (en) | 2015-12-23 |
RU2014140608A (ru) | 2016-04-27 |
EP2637023A1 (en) | 2013-09-11 |
IN2014DN07813A (pt) | 2015-07-10 |
US20150080246A1 (en) | 2015-03-19 |
HK1198556A1 (en) | 2015-05-15 |
EP2823314A1 (en) | 2015-01-14 |
EP3232201A1 (en) | 2017-10-18 |
EP2823314B1 (en) | 2017-04-12 |
JP6117251B2 (ja) | 2017-04-19 |
DK2823314T3 (en) | 2017-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014019349A8 (pt) | Previsão do resultado nos pacientes com doença pulmonar obstrutiva crônica | |
Meng et al. | Deferoxamine alleviates chronic hydrocephalus after intraventricular hemorrhage through iron chelation and Wnt1/Wnt3a inhibition | |
BRPI0906683B8 (pt) | método para medir e caracterizar microvesículas em fluidos corporais humanos | |
HRP20180002T1 (hr) | Kompozicije i postupci za liječenje karcinoma | |
Jaffar et al. | Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis | |
MX2018003376A (es) | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. | |
BRPI1007321A2 (pt) | métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo. | |
NZ606495A (en) | Biomarker assays for detecting or measuring inhibition of tor kinase activity | |
BR112017017076A2 (pt) | inibidor de il-18, anticorpo, métodos para o tratamento de uma doença ou um distúrbio associado a il-18 em um indivíduo, para determinar a quantidade de il-18 livre em uma amostra ou in situ, para diagnosticar uma predisposição a uma doença ou um distúrbio associado a il-18, para monitorar doença residual mínima em um paciente que segue o tratamento com o inibidor de il-18 ou a composição e para prever uma resposta de um paciente a um tratamento com o inibidor de il-18 ou composição, e, kit diagnóstico para detectar il-18 livre. | |
RU2017126701A (ru) | Способ детекции нуклеосом, содержащих нуклеотиды | |
BR112014024219A8 (pt) | Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit | |
BRPI0917948A2 (pt) | métodos de identificar uma variante genética que está associada com o desenvolvimento de uma condição de interesse e um paciente em um ensaio clínico de um tratamento para doença de alzheimer, de determinar riscos incrementando de desenvolvimento de uma condição de interesse, doença de alzheimer em um paciente, de um prognóstico ou o risco de desenvolver doença de alzheimer em um paciente, de tratar um paciente para doença de alzheimer, uma condição de interesse e doença de alzheimer em um paciente, de estratificar um paciente em um subgrupo de um ensaio clínico de uma terapia para o tratamento de doença de alzheimer, uso de um agente ativo anti-doença de alzheimer e kits para determinar se um paciente encontra-se em risco incrementado de desenvolver doença de alzheimer e se um paciente é responsivo a tratamento para uma condição de interesse | |
BR112018010269A2 (pt) | mr-proadm como marcador para o status do volume extracelular de um indivíduo | |
BR112012008665A2 (pt) | tratamento de câncer | |
AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
BR112013028808A2 (pt) | métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada | |
BR112015004229A2 (pt) | ensaios de diagnósticos e kits para a deteção de receptor 1 do folato | |
JP2015501297A5 (ja) | 医薬組成物、方法、診断キット | |
BRPI0507442B8 (pt) | método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia | |
BR112012031389A2 (pt) | método para prever os resultados clínicos para pacientes com melanoma usando células de melanoma circulantes no sangue | |
JP2016118568A5 (pt) | ||
ATE531725T1 (de) | Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen | |
CA2863393A1 (en) | A multi-biomarker-based outcome risk stratification model for pediatric septic shock | |
RU2011111875A (ru) | Способ прогнозирования развития осложнений у больных внебольничной пневмонией | |
RU2012127032A (ru) | Способ прогнозирования риска раннего развития атеросклероза у больных хроническим простатитом |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |